Clinical Trial Update: TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating TAR-0520 Gel for EGFR inhibitor–induced folliculitis and rash, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Folliculitis
• Rash

Drugs mentioned

• TAR-0520 Gel (TAR-0520)

Snippet

Sponsor: Tarian Pharma | Conditions: EGFR Inhibitor-associated Rash | Phase 2 | Status: RECRUITING